 The studys primary objective in a population of patients with MDS after failure of treatment with azacitidine AZA or decitabine DAC, is to compare the overall survival OS of patients in the rigosertib group vs the Physicians Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk. 